We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

Bruker Announces Progress in Advanced Methods and Software Tools for 4D High-Throughput and Ultra-High Sensitivity Proteomics

Rectangle Image
Product News

Bruker Announces Progress in Advanced Methods and Software Tools for 4D High-Throughput and Ultra-High Sensitivity Proteomics

The timsTOF Pro
At the 15th Annual Conference of the US Human Proteome Organization, Bruker announced further progress in high-sensitivity, high-throughput plasma-proteomics using the timsTOF Pro mass spectrometer connected to an Evosep One low-flow chromatography system. Bruker also highlights advances in PEAKS, Protein Metrics, and MaxQuant 4D proteomics software supporting routine acquisition and information extraction using large-scale accurate collision cross section (CCS) values.

The timsTOF Pro with its unique PASEF (Parallel Accumulation Serial Fragmentation) capability allows the acquisition of ion mobility information at high throughput and with ultra-high sensitivity, resulting in the large-scale calculation of accurate collisional cross sections. Using novel 4D algorithms in PEAKS Studio software resulted in a dramatic increase of quantified proteins across a 192-sample cohort of septic shock patients, acquired at a rate of 100 samples/day:

Dr. Roman Fischer, Nuffield Department of Medicine, Project Leader - Discovery Proteomics, at Oxford University, Oxford, UK, said: "The 4D feature matching capability enabled by TIMS, boosts the number of quantified plasma proteins in a single 11.5 min LC-MS/MS run with low sample amounts injected. Collectively, there were 772 plasma proteins quantified with 100ng injected using these short gradients, where 66% of the identifications correspond to only 10% of the protein mass of plasma. This demonstrates that the method can achieve sufficient depth to discover biomarkers on low abundance proteins. Achieving this depth on the timsTOF Pro offers completely new possibilities to analyze large sample cohorts of hundreds to thousands of samples for biomarker discovery in blood plasma."

Dr. Gary Kruppa, Vice President Proteomics at Bruker Daltonics, commented: "A common practice to achieve greater proteomic depth is sample pre-fractionation. However, this results in long measurement times, which is often compensated by multiplexing and chemical labeling. Although isobaric labeling methods seem attractive in principle, they suffer from ratio distortion that can skew or compromise quantification of low-abundance proteins between samples. A label-free quantitation approach combining short LC gradients with high selectivity of 4D matching is available only on the timsTOF Pro, and provides a compelling alternative that can be applied to thousands of samples in high-throughput proteomics."

Key new software developments shown at US HUPO 2019 include the release of PEAKS On-line for the timsTOF Pro, a server software that is parallelized with the ability to run on clusters or multi-CPU machines. In combination with the new denoising algorithm in timsTOF Pro acquisition software, which reduces the data file size by a factor 5x to 10x without any noticeable loss of information, the scalable performance of PEAKS Online facilitates state-of-the-art high-throughput proteomics experiments.

Protein Metrics Inc (PMI) also added peptide CCS support to their Byonic database search algorithm, which is well accepted by pharmaceutical and biopharma scientists for HCP and other biologics characterization and discovery workflows.

Dr. Eric Carlson, President and CEO of Protein Metrics Inc., stated: "We are thrilled to include the analysis of timsTOF Pro and PASEF data in our software for our customers. For applications such as disulfide bond analysis, glycoanalysis, and host cell proteins, the ability to include ion mobility and CCS data as the 4th dimension of separation, will provide even deeper insights into protein samples to drive drug discovery and development."
Advertisement